Yaping Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yaping Gu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Neena Singh
The Institute of Pathology, Case Western Reserve University, 2085, Adelbert Road, Cleveland, Ohio 44106, USA
5 shared publicationsRavi Shankar Mishra
The Institute of Pathology, Case Western Reserve University, 2085, Adelbert Road, Cleveland, Ohio 44106, USA
4 shared publicationsSharmila Bose
The Institute of Pathology, Case Western Reserve University, 2085, Adelbert Road, Cleveland, Ohio 44106, USA
3 shared publicationsHisashi Fujioka
From the Institute of Pathology, Case Western Reserve University, Cleveland, Ohio
2 shared publicationsRuliang Li
The Institute of Pathology, Case Western Reserve University, 2085, Adelbert Road, Cleveland, Ohio 44106, USA
2 shared publicationsSudheera Kalepu
From the Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106
2 shared publications
Latest Publications
- 27 January 2003
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 5 (1) , 15-23
Aggresome formation by mutant prion proteins: The unfolding role of proteasomes in familial prion disorders
Although familial prion disorders are a direct consequence of mutations in the prion protein gene, the underlying mechanisms leading to neurodegeneration remain unclear. Potential pathogenic mechanisms include abnormal cellular metabolism of the muta
- 27 January 2003
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 5 (1) , 15-23
Aggresome formation by mutant prion proteins: The unfolding role of proteasomes in familial prion disorders
Although familial prion disorders are a direct consequence of mutations in the prion protein gene, the underlying mechanisms leading to neurodegeneration remain unclear. Potential pathogenic mechanisms include abnormal cellular metabolism of the muta
- Open Access
- 1 July 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (27) , 24554-24561
Cell Surface Accumulation of a Truncated Transmembrane Prion Protein in Gerstmann-Straussler-Scheinker Disease P102L
- 1 July 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (27) , 24554-24561
Open AccessCell Surface Accumulation of a Truncated Transmembrane Prion Protein in Gerstmann-Straussler-Scheinker Disease P102L
- 1 January 2002
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 7 (1) , a60-71
Prion peptide 106-126 as a model for prion replication and neurotoxicity
Prion diseases or transmissible spongiform encephalopathies are neurodegenerative disorders that are genetic, sporadic, or infectious. The pathogenetic event common to all prion disorders is a change in conformation of the cellular prion protein (PrPC) to the scrapie isoform (PrPSc), which, unlike PrPC, aggregates easily and is partially resistant to protease digestion. Although PrPSc is believed to be essential for the pathogenesis and transmission of prion disorders, the mechanism by which PrPSc deposits cause neurodegeneration is unclear. It has been proposed that in some cases of prion disorders, a transmembrane form of PrP, termed CtmPrP may be the mediator of neurodegenerative changes rather than PrPSc per se. In order to understand the underlying cellular processes by which PrPSc mediates neurodegeneration, we have investigated the mechanism of neurotoxicity by a beta-sheet rich peptide of PrP in a cell model. We show that exposure of human neuronal cell lines NT-2 and M17 to the prion peptide 106-126 (PrP106-126) catalyzes the aggregation of endogenous cellular prion protein (PrPC) to an amyloidogenic form that shares several characteristics with PrPSc. Intracellular accumulation of these PrPSc-like forms upregulates the synthesis of CtmPrP, which is proteolytically cleaved in the endoplasmic reticulum and the truncated C-terminal fragment is transported to the cell surface. In addition, we have isolated mutant NT-2 and neuroblastoma cells that are resistant to toxicity by PrP106-126 to facilitate further characterization of the biochemical pathways of PrP106-126 neurotoxicity. The PrP106-126-resistant phenotype of these cells could result from aberrant binding or internalization of the peptide, or due to an abnormality in the downstream pathway(s) of neuronal toxicity. Thus, our data suggest that PrPSc aggregation occurs by a process of 'nucleation' on a pre-existing 'seed' of PrP. Furthermore, the PrP106-126-resistant cells reported here will provide a unique opportunity for identifying the cellular and biochemical pathways that mediate neurotoxicity by PrPSc.
- 1 January 2002
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 7 (1) , a60-71
Prion peptide 106-126 as a model for prion replication and neurotoxicity
Prion diseases or transmissible spongiform encephalopathies are neurodegenerative disorders that are genetic, sporadic, or infectious. The pathogenetic event common to all prion disorders is a change in conformation of the cellular prion protein (PrPC) to the scrapie isoform (PrPSc), which, unlike PrPC, aggregates easily and is partially resistant to protease digestion. Although PrPSc is believed to be essential for the pathogenesis and transmission of prion disorders, the mechanism by which PrPSc deposits cause neurodegeneration is unclear. It has been proposed that in some cases of prion disorders, a transmembrane form of PrP, termed CtmPrP may be the mediator of neurodegenerative changes rather than PrPSc per se. In order to understand the underlying cellular processes by which PrPSc mediates neurodegeneration, we have investigated the mechanism of neurotoxicity by a beta-sheet rich peptide of PrP in a cell model. We show that exposure of human neuronal cell lines NT-2 and M17 to the prion peptide 106-126 (PrP106-126) catalyzes the aggregation of endogenous cellular prion protein (PrPC) to an amyloidogenic form that shares several characteristics with PrPSc. Intracellular accumulation of these PrPSc-like forms upregulates the synthesis of CtmPrP, which is proteolytically cleaved in the endoplasmic reticulum and the truncated C-terminal fragment is transported to the cell surface. In addition, we have isolated mutant NT-2 and neuroblastoma cells that are resistant to toxicity by PrP106-126 to facilitate further characterization of the biochemical pathways of PrP106-126 neurotoxicity. The PrP106-126-resistant phenotype of these cells could result from aberrant binding or internalization of the peptide, or due to an abnormality in the downstream pathway(s) of neuronal toxicity. Thus, our data suggest that PrPSc aggregation occurs by a process of 'nucleation' on a pre-existing 'seed' of PrP. Furthermore, the PrP106-126-resistant cells reported here will provide a unique opportunity for identifying the cellular and biochemical pathways that mediate neurotoxicity by PrPSc.
- Open Access
- 1 January 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (3) , 2275-2286
Prion Peptide 106–126 Modulates the Aggregation of Cellular Prion Protein and Induces the Synthesis of Potentially Neurotoxic Transmembrane PrP
- 1 January 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (3) , 2275-2286
Open AccessPrion Peptide 106–126 Modulates the Aggregation of Cellular Prion Protein and Induces the Synthesis of Potentially Neurotoxic Transmembrane PrP
- 14 May 2001
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 3 (2) , 169-180
Isolation of human neuronal cells resistant to toxicity by the prion protein peptide 106-126
Prion diseases or transmissible spongiform encephalopathies, are neurodegenerative disorders that are genetic, sporadic, or infectious. The pathogenetic event common to all prion disorders is the conformational transformation of the cellular prion pr
- 14 May 2001
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 3 (2) , 169-180
Isolation of human neuronal cells resistant to toxicity by the prion protein peptide 106-126
Prion diseases or transmissible spongiform encephalopathies, are neurodegenerative disorders that are genetic, sporadic, or infectious. The pathogenetic event common to all prion disorders is the conformational transformation of the cellular prion pr